Merck & Co., Inc. vs Schwab US Large Cap Growth ETF — how do they compare? Merck & Co., Inc. trades at $133.35 (market cap $321.77B), while Schwab US Large Cap Growth ETF trades at $35.63. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals.
| MRK | SCHG | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Sector/Thematic |
52-Week High | $131.84 | $35.83 |
52-Week Low | $77.60 | $28.10 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
SCHG trades at $35.61, down 0.61% today, with a bullish technical trend supported by moving averages but neutral oscillators. The ETF focuses on U.S. large-cap growth stocks, benefiting from AI and technology themes, though key financial ratios are not disclosed in the provided data. Recent news highlights its low 0.04% expense ratio and strong historical performance, with institutional activity showing mixed positions.
Outlook remains positive due to exposure to growth sectors like AI, but risks include high concentration in top holdings and sensitivity to interest rates. Analyst sentiment is generally favorable, emphasizing long-term growth potential despite valuation concerns.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →